Skip to main content
Premium Trial:

Request an Annual Quote

Penn State Hershey Children's Hospital, Serametrix Collaborate on CDx for Brain Cancer

NEW YORK (GenomeWeb News) – Penn State Hershey Children's Hospital and Serametrix today announced a collaboration to develop a companion diagnostic test for predicting patient response to a novel immunotherapy for brain cancer.

The deal is part of the Pediatric Cancer Immunotherapy Program at the hospital, which provides therapies aimed at children with relapsed tumors. The hospital has novel immune-based therapies for pediatric patients with relapsed neuroblastoma and sarcoma, and as part of the collaboration Serametrix will analyze about 100 samples from patients enrolled in trials for the therapies during the next year, the partners said.

Financial and other terms of the deal were not disclosed.

Based in Carlsbad, Calif., Serametrix develops technologies to detect changes in serum for personalized medicine-based approaches. The firm said it has identified tumor antigen panels for predicting clinical response in cancer types, including melanoma, colorectal cancer, breast cancer, and glioblastoma.

The Scan

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.